Olema Pharmaceuticals (OLMA) Total Liabilities (2020 - 2026)
Olema Pharmaceuticals (OLMA) posted quarterly Total Liabilities of $50.2 million for Q1 2026, up 91.57% year-over-year from $26.2 million in Q1 2025, and down 8.57% quarter-over-quarter from $54.9 million in Q4 2025.
Olema Pharmaceuticals (OLMA) Total Liabilities (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has reported Total Liabilities for 7 consecutive years, with $50.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 91.57% year-over-year to $50.2 million; the TTM figure through Mar 2026 stood at $50.2 million (up 91.57% YoY), while the FY2025 annual figure was $54.9 million, up 30.6% from the prior year.
- Total Liabilities eased to $50.2 million in Q1 2026 per OLMA's latest filing, from $54.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $54.9 million in Q4 2025 and bottomed at $12.3 million in Q1 2022.
- Historically, Total Liabilities has averaged $28.1 million across 5 years, with a median of $26.2 million in 2025.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 133.62% — and 2025, when it decreased 4.34%.
- Olema Pharmaceuticals' Total Liabilities stood at $18.1 million in 2022, then climbed by 27.36% to $23.0 million in 2023, then soared by 82.28% to $42.0 million in 2024, then soared by 30.6% to $54.9 million in 2025, then dropped by 8.57% to $50.2 million in 2026.
- Business Quant data shows OLMA's Total Liabilities at $50.2 million in Q1 2026, $54.9 million in Q4 2025, and $45.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Olema Pharmaceuticals | 930.10 Mn | 930.10 Mn | - | 56.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 56.01 Mn |
| Mar 31, 2026 | 50.17 Mn |
| Dec 31, 2025 | 54.87 Mn |
| Sep 30, 2025 | 44.97 Mn |
| Jun 30, 2025 | 36.77 Mn |
| Mar 31, 2025 | 26.19 Mn |
| Dec 31, 2024 | 42.02 Mn |
| Sep 30, 2024 | 31.26 Mn |
| Jun 30, 2024 | 27.39 Mn |
| Mar 31, 2024 | 27.38 Mn |
| Dec 31, 2023 | 23.05 Mn |
| Sep 30, 2023 | 17.67 Mn |
| Jun 30, 2023 | 16.04 Mn |
| Mar 31, 2023 | 20.79 Mn |
| Dec 31, 2022 | 18.10 Mn |
| Sep 30, 2022 | 14.30 Mn |
| Jun 30, 2022 | 14.32 Mn |
| Mar 31, 2022 | 12.33 Mn |
| Dec 31, 2021 | 11.38 Mn |
| Sep 30, 2021 | 8.90 Mn |